NewAmsterdam Pharma Co N.V. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
NewAmsterdam Pharma Co N.V. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2023 to Q3 2024.
  • NewAmsterdam Pharma Co N.V. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$16.6M, a 64.7% increase year-over-year.
  • NewAmsterdam Pharma Co N.V. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$199M.
  • NewAmsterdam Pharma Co N.V. annual Net Income (Loss) Attributable to Parent for 2023 was -$177M, a 682% decline from 2022.
  • NewAmsterdam Pharma Co N.V. annual Net Income (Loss) Attributable to Parent for 2022 was -$22.6M, a 45.8% increase from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$199M -$16.6M +$30.5M +64.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-06
Q2 2024 -$229M -$39M -$716K -1.87% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 -$229M -$93.8M -$51.7M -123% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$177M -$49.5M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 -$47.1M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 -$38.3M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$42M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.